Biotech

Biotech Timmy Broderick

STAT Plus: Gene therapies for deafness dredge up an old question: Do deaf people want a ‘cure’?

Biotech Jason Mast

STAT Plus: Duchenne muscular dystrophy drug from Nippon Shinyaku fails in rare confirmatory trial

The Readout Meghana Keshavan

STAT Plus: More tumult at BIO amid the company’s fourth CEO in four years

Biotech Elaine Chen

STAT Plus: Ozempic cut risk of death in diabetes patients with chronic kidney disease

Biotech Angus Chen and Jonathan Wosen

STAT Plus: FDA advisers endorse Guardant Health’s colon cancer screening test

Biotech Allison DeAngelis

STAT Plus: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical

The Readout Elaine Chen

STAT Plus: In light of H5N1 outbreak, U.S. in talks with mRNA vaccine makers on bird flu

Adam's Take Adam Feuerstein

STAT Plus: Setting the table: What to expect at this year’s ASCO meeting

Biotech Allison DeAngelis and Elaine Chen

STAT Plus: Biotechs turn to gene silencing for obesity drugs that can last longer than Wegovy

Biotech Matthew Herper and Elaine Chen

STAT Plus: Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575 million, lowering hopes of a buyout

The Readout Elaine Chen

STAT Plus: Maryland takes first steps to cap drug costs

Biotech Allison DeAngelis

STAT Plus: Biogen joins immunology wave with $1.15 billion acquisition

Biotech Andrew Joseph

STAT Plus: At a flashy new research hub, AstraZeneca lays out ambitious growth goals

The Readout Elaine Chen

STAT Plus: Lilly doubles down on radiopharma

Biotech Jonathan Wosen

STAT Plus: AltruBio raises $225 million to develop ulcerative colitis drug and other immune checkpoint enhancers

Biotech Allison DeAngelis

STAT Plus: GSK’s asthma push continues as drug succeeds in Phase 3 trials

Health tech Casey Ross and Matthew Herper

STAT Plus: AI & drug discovery: A biotech CEO, a scientist, and a venture capitalist separate hype from reality

The Readout Meghana Keshavan

STAT Plus: The biotech news you need to read this morning

Biotech Elaine Chen

STAT Plus: Amid acquisition speculation, Cytokinetics CEO stresses company can launch heart drug on its own

The Readout Meghana Keshavan

AstraZeneca antibody reduced Covid-19 risk in immunocompromised

The Readout LOUD Allison DeAngelis and Adam Feuerstein

STAT Plus: Listen: Live! From the STAT Breakthrough Summit West

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: PDS Biotech’s survival benefit is absurdly overstated

Biotech Jason Mast

STAT Plus: Biogen, Ionis drop ALS treatment after study failure

The Readout Elaine Chen

STAT Plus: Blackstone wants in on red-hot immunology market

Biotech Elaine Chen

STAT Plus: Lilly’s weekly insulin works as well as daily products, new studies show

Biotech Andrew Joseph

STAT Plus: Galapagos, in makeover mode, strikes deal to make CAR-T therapies at blood centers across U.S.

Politics John Wilkerson

STAT Plus: WuXi Biologics execs register to lobby as Congress comes for the company

The Readout Elaine Chen

STAT Plus: Leqembi gets closer to being offered as an injection

The Readout Elaine Chen

Is Novavax a new meme stock?